Functional studies in different forms of hyperkinetic movement disorders

Conditions: Jerky movement disorders
motor tics
10028037

Registration Number: NL-OMON32146

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

Group 1: Psychogenic movement disorders: We will include patients with *clinically established psychogenic movement disorders*, as defined by Hinson and colleagues and Williams and colleagues . This means movements incongruent with organic disease or inconsistent symptoms, in addition to the presence of other false neurological signs or multiple somatisations.
Group 2 : Gilles de la Tourette: DSM-IV diagnosis plus jerky movements of limbs.
Group 3: MD patients with proven DYT 11 mutation and DYT11 negative MD patients (the latter for EMG-fMRI only).
All patients should have jerky movements frequently.

Exclusion Criteria

General exclusion criteria are neurological co-morbidity and the use of substance and/or medication that may influence study results. For the fMRI-EMG study extra exclusion criteria apply. Participants should not have metal implants (e.g. pacemaker), nor should they be pregnant. Moreover, participants with claustrofobia are excluded from fMRI investigation.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The purpose of this study is to obtain a better understanding of the<br /><br>pathophysiological substrate of jerky movements. We want to identify brain<br /><br>activations and areas involved with EMG-fMRI that differentiate between MD, GTS<br /><br>and psychogenic movement disorders and we want to identify different activation<br /><br>patterns with EEG-EMG analysis techniques. All findings will be analyzed with<br /><br>respect to common psychiatric co-morbidity, as objectified with standardized<br /><br>psychiatric scales. The final goal is to use these functional studies for<br /><br>future clinical practice to discriminate psychogenic and neurological<br /><br>hyperkinetic movement disorders and guide treatment strategy.</p><br>

Secondary Outcome Measures